1-3 of 3
Zachary F. Zimmerman, MD PhD
Close
Sort by
Journal Articles

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Max S. Topp, MD, Zachary F. Zimmerman, MD PhD, Paul Cannell, MD, Herve Dombret, MD, Anthony S. Stein, MD, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong, PhD, Andre Schuh, MD FRCPC
Journal: Blood
Blood (2017) 130 (Supplement 1): 2571.
https://doi.org/10.1182/blood.V130.Suppl_1.2571.2571
Published: 2017
Journal Articles

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Alessandro Rambaldi, MD Prof, Françoise Rigal-Huguet, MD, Pavel Zak, Paul Cannell, MD, Kun Nie, PhD, Zachary F. Zimmerman, MD PhD, Max S. Topp, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2552.
https://doi.org/10.1182/blood.V130.Suppl_1.2552.2552
Published: 2017
Journal Articles

Baseline Biomarkers Influencing Clinical Outcomes in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Treated with Blinatumomab Versus Standard-of-Care Chemotherapy (SOC) from a Randomized Phase 3 Study

Andrew Wei, MBBS, PhD FRACP, FRCPA, Josep-Maria Ribera, MD, Giovanni Martinelli, Richard A. Larson, MD, David Ritchie, MD PhD, Armin Ghobadi, MD, Yuqi Chen, Cedric E. Dos Santos, Zachary F. Zimmerman, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2556.
https://doi.org/10.1182/blood.V130.Suppl_1.2556.2556
Published: 2017